These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 27464593

  • 21. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
    Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, Singh S.
    Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
    [Abstract] [Full Text] [Related]

  • 22. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [Abstract] [Full Text] [Related]

  • 23. Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature.
    Kalil JR, Cerqueira LA, Barbosa DS, Motta MP, Nery Mda S, Bittencourt PL.
    Arq Gastroenterol; 2009 Jan; 46(3):214-8. PubMed ID: 19918689
    [Abstract] [Full Text] [Related]

  • 24. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
    Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, Pereira G, Poca M, Sánchez J, Guevara M, Soriano G, Alessandria C, Fernández J, Arroyo V, Ginès P.
    J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
    [Abstract] [Full Text] [Related]

  • 25. Terlipressin for hepatorenal syndrome.
    Gluud LL, Christensen K, Christensen E, Krag A.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD005162. PubMed ID: 22972083
    [Abstract] [Full Text] [Related]

  • 26. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.
    Hepatology; 2002 Oct 12; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [Abstract] [Full Text] [Related]

  • 27. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome.
    Hepatology; 2015 Aug 12; 62(2):567-74. PubMed ID: 25644760
    [Abstract] [Full Text] [Related]

  • 28. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P, TAHRS Investigators.
    Gastroenterology; 2008 May 12; 134(5):1352-9. PubMed ID: 18471512
    [Abstract] [Full Text] [Related]

  • 29. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
    Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Terlipressin Study Group.
    Liver Transpl; 2011 Nov 12; 17(11):1328-32. PubMed ID: 21837734
    [Abstract] [Full Text] [Related]

  • 30. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M.
    Eur J Gastroenterol Hepatol; 2002 Dec 12; 14(12):1363-8. PubMed ID: 12468959
    [Abstract] [Full Text] [Related]

  • 31. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
    Wang H, Liu A, Bo W, Feng X, Hu Y.
    Medicine (Baltimore); 2018 Apr 12; 97(16):e0431. PubMed ID: 29668606
    [Abstract] [Full Text] [Related]

  • 32. Terlipressin in hepatorenal syndrome.
    Mazur JE, Cooper TB, Dasta JF.
    Ann Pharmacother; 2011 Mar 12; 45(3):380-7. PubMed ID: 21386023
    [Abstract] [Full Text] [Related]

  • 33. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF.
    Gastroenterology; 2002 Apr 12; 122(4):923-30. PubMed ID: 11910344
    [Abstract] [Full Text] [Related]

  • 34. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M, Götz E, Scholz-Kreisel P, Ahrens J, Sivanathan V, Schattenberg J, Rey JW, Wörns MA, Galle PR, Marquardt JU.
    Dtsch Med Wochenschr; 2015 Jan 12; 140(2):e21-6. PubMed ID: 25612289
    [Abstract] [Full Text] [Related]

  • 35. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
    Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F.
    Hepatology; 2007 Dec 12; 46(6):1863-71. PubMed ID: 18027874
    [Abstract] [Full Text] [Related]

  • 36. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
    Wong F, Boyer TD, Sanyal AJ, Pappas SC, Escalante S, Jamil K.
    Nephrol Dial Transplant; 2020 Sep 01; 35(9):1554-1561. PubMed ID: 30887050
    [Abstract] [Full Text] [Related]

  • 37. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
    Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.
    J Hepatol; 2007 Oct 01; 47(4):499-505. PubMed ID: 17560680
    [Abstract] [Full Text] [Related]

  • 38. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
    Hinz M, Wree A, Jochum C, Bechmann LP, Saner F, Gerbes AL, Gerken G, Canbay A.
    Ann Hepatol; 2013 Oct 01; 12(1):92-9. PubMed ID: 23293199
    [Abstract] [Full Text] [Related]

  • 39. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
    Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM.
    PLoS One; 2014 Oct 01; 9(9):e107466. PubMed ID: 25203311
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA, Huang X, Jamil K, Corman S, Ektare V, Niewoehner J.
    J Med Econ; 2023 Oct 01; 26(1):1342-1348. PubMed ID: 37729445
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.